Anumana Appoints Harry S. Palmin as CFO
14 Mayo 2024 - 6:05AM
Business Wire
Anumana, a leading AI-driven health technology company and
portfolio company of nference, today announced the appointment of
Harry S. Palmin as chief financial officer (CFO). As a veteran in
building, financing, and operating life sciences companies, Palmin
brings over 25 years of experience to Anumana’s executive
leadership team. In his new role, he will lead financial
operations, investor relations, and corporate development
activities at Anumana, and guide the company’s strategic growth. In
addition to his role as CFO of Anumana, Palmin joins nference as
CFO, Ventures.
Palmin's distinguished career includes tenure as CFO at Acer
Therapeutics Inc., where he played a pivotal role in the company's
successful acquisition by Zevra Therapeutics, Inc. His leadership
was instrumental in Acer's public offering and the company’s FDA
approval for OLPRUVATM, a treatment for urea cycle disorders. Prior
to his role at Acer, Palmin served in multiple executive positions
at Novelos Therapeutics, Inc., where he helped transform the
company from conceptual stage into a leading public oncology and
infectious disease development entity.
“Harry is a highly skilled and accomplished executive with a
proven track record in building successful companies in the life
sciences industry,” said Maulik Nanavaty, CEO of Anumana. “I am
thrilled to welcome Harry to Anumana at an exciting time for the
company, where we are making tremendous progress in pipeline
development and commercial traction. I look forward to partnering
with him through our next phase of growth.”
Anumana is at the forefront of revolutionizing healthcare with
its groundbreaking ECG-AITM platform that, from standard ECGs at
the point of care, enables the identification of hidden
cardiovascular diseases for which effective, lifesaving treatments
may be available. The ECG-AI platform won the 2024 MedTech
Breakthrough Award for “Best New Technology Solution-
Cardiology.”
The company’s lead algorithm, ECG-AI LEF, an FDA Breakthrough
Device-designated medical device, recently received FDA clearance
for detecting low ejection fraction, a common undiagnosed indicator
of heart failure1 and prevalent progressive disease that affects
over 6 million people in the U.S. and is associated with a
significant total annual healthcare cost.2 Anumana’s expansive
development pipeline also includes three additional algorithms with
FDA Breakthrough Device designation (pulmonary hypertension,
cardiac amyloidosis, and hyperkalemia). The company has multiple
ongoing partnerships with leading pharmaceutical companies to
further develop and commercialize algorithms in its pipeline.3,4
Anumana also spearheaded the effort to bring reimbursement to
ECG-AI, receiving approval for two Category III CPT® codes from the
American Medical Association in 2022. These codes are now available
and designed to facilitate the use, adoption, and potential
reimbursement of emerging technologies in clinical workflows.5
“Anumana is one of the most innovative companies in healthcare
technology and it is an honor to be joining the organization at
such a pivotal time in its growth,” said Palmin. “The progress
Anumana has accomplished in just three years since its founding and
the potential impact that Anumana’s AI technology platform can make
on patient outcomes are inspiring. I am excited to be part of the
team and the mission to use pioneering AI technology to unlock the
electrical language of the heart and improve patient care.”
Palmin earned a B.A. in economics and business and an M.A. in
international economics and finance from the International Business
School at Brandeis University. He also studied at the London School
of Economics and the Copenhagen Business School.
About Anumana
Anumana is a leading AI-driven health technology company
leveraging cutting-edge AI and industry-leading translational
science to unlock the electrical language of the heart as never
before. The company was founded by nference in collaboration with
Mayo Clinic to leverage the clinical and technical expertise of
both organizations, to develop innovative ECG-AI technology into a
clinically meaningful, medical-grade, and easy-to-use tool for
clinicians to advance patient care. Anumana’s software-as-a-medical
device (SaMD) ECG-AI solutions aim to detect hidden diseases using
standard of care ECG readings, enabling clinicians to enhance and
improve care with real-time AI insights.
Anumana’s lead algorithm, ECG-AI™ LEF, is now available in the
U.S. To learn more about how the algorithm can help clinicians
identify low ejection fraction (LEF) earlier and schedule a demo,
visit us at ECG-AI LEF.
Anumana was named one of Fierce MedTech’s Fierce 15 companies
for 2022. Follow Anumana at anumana.ai and on LinkedIn and
Twitter.
About nference
nference is unlocking the potential of healthcare data with AI,
delivering real-world evidence, insights, and solutions informed by
the most comprehensive multimodal data across all therapeutic
areas. The company’s extensive de-identified, longitudinal data
includes decades of clinical notes along with rich patient
histories, vitals, lab tests, radiology images, digital pathology,
genomics, and electrophysiology waveforms. Our federated data
platform, comprising premier healthcare organizations, including
Mayo Clinic, Duke Health, Banner Health, Vanderbilt University
Medical Center, and Emory Healthcare, enables advanced research and
custom AI model development. With unprecedented access to data from
over 40 million patient journeys, our partners can accelerate
target discovery, optimize clinical trial design, and enhance
lifecycle management. Follow nference on LinkedIn. Visit us at
www.nference.com.
References
- Jaskanwal D Sara, Takumi Toya, Riad Taher, Amir Lerman, Bernard
J Gersh, Nandan S Anavekar. Asymptomatic Left Ventricle Systolic
Dysfunction. European Cardiology Review 2020, 15:e13;
https://doi.org/10.15420/ecr.2019.14.
- Khazanie P, Allen LA. Systematizing Heart Failure Population
Health. Heart Fail Clin. 2020 Oct;16(4):457-466. doi:
10.1016/j.hfc.2020.06.006. Epub 2020 Jul 21. PMID: 32888640; PMCID:
PMC7737815;
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737815/.
- Anumana and Pfizer Partner to Enable Early Detection of
Underdiagnosed Cardiovascular Disease
- Anumana Collaborates with Leading Global Health Care Company to
Detect Heart Disease Using Artificial Intelligence
- Anumana Announces issuance of New American Medical Association
CPT® Category III codes for Novel ECG AI Analysis of Cardiac
Dysfunctions
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240514546702/en/
Sam Choinski Pazanga Health Communications for Anumana
schoinski@pazangahealth.com (860) 301-5058